Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) Invested Capital (2020 - 2025)

Historic Invested Capital for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to $266.6 million.

  • Arcutis Biotherapeutics' Invested Capital fell 2620.85% to $266.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $266.6 million, marking a year-over-year decrease of 2620.85%. This contributed to the annual value of $264.7 million for FY2024, which is 885.54% down from last year.
  • Arcutis Biotherapeutics' Invested Capital amounted to $266.6 million in Q3 2025, which was down 2620.85% from $247.0 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Invested Capital registered a high of $467.5 million during Q3 2022, and its lowest value of $247.0 million during Q2 2025.
  • Its 5-year average for Invested Capital is $338.6 million, with a median of $338.5 million in 2023.
  • As far as peak fluctuations go, Arcutis Biotherapeutics' Invested Capital soared by 10973.76% in 2021, and later tumbled by 4706.19% in 2023.
  • Arcutis Biotherapeutics' Invested Capital (Quarter) stood at $370.0 million in 2021, then grew by 10.09% to $407.3 million in 2022, then dropped by 28.69% to $290.5 million in 2023, then fell by 8.86% to $264.7 million in 2024, then grew by 0.69% to $266.6 million in 2025.
  • Its Invested Capital stands at $266.6 million for Q3 2025, versus $247.0 million for Q2 2025 and $250.3 million for Q1 2025.